Source: International Congress 2018 – COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Anees (Windsor, Canada), A. Mcivor (Hamilton, Canada), K. Chapman (Toronto, Canada), I. Mayers (Edmonton, Canada), D. Rochdi (Dorval, Canada), D. Prefontaine (Dorval, Canada), A. Kaplan (Toronto, Canada). Health status changes in COPD patients after real-life switch from tiotropium or salmeterol/fluticasone to indacaterol/glycopyrronium using the EQ-5D-3L instrument: results from the POWER study. 4380

Member's Comments

No comment yet.

Related content which might interest you: Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004 Improving morning activities in COPD patients with budesonide/formoterol: Assessment of data from two randomised trials using minimal important differences from a morning activities questionnaire Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Evaluation of roflumilast in COPD patients in a real-world European setting: results from the PROFILE EU study Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017 COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007 Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: the real-life data Source: International Congress 2018 – Tests and trends in asthma Year: 2018 Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Combined tiotropium + olodaterol influences physical functioning in COPD: Results of an open-label observational study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Patient-reported outcomes (PROs) and reliever use in Japanese and European patients with chronic obstructive pulmonary disease receiving formoterol 4.5 and 9μg twice daily: Results of the OCEAN phase III study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Budesonide/formoterol improves the wellbeing of patients with COPD: results from a real-life setting Source: Eur Respir J 2005; 26: Suppl. 49, 289s Year: 2005 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design Source: ERJ Open Res, 5 (4) 00061-2019; 10.1183/23120541.00061-2019 Year: 2019 Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015